We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Rheumatology

Journal Scan / Research · June 03, 2021

Half-Dose vs Stable-Dose Conventional Synthetic DMARDs on Disease Flares in Patients With RA in Remission

JAMA: The Journal of the American Medical Association

 

Additional Info

JAMA: The Journal of the American Medical Association
Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial
JAMA 2021 May 04;325(17)1755-1764, S Lillegraven, N Paulshus Sundlisæter, AB Aga, J Sexton, IC Olsen, H Fremstad, C Spada, TM Madland, CA Høili, G Bakland, Å Lexberg, IJW Hansen, IM Hansen, H Haukeland, MA Ljoså, E Moholt, T Uhlig, DH Solomon, D van der Heijde, TK Kvien, EA Haavardsholm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading